Current and future treatment modalities for Clostridium difficile-associated disease (Q34767527)

4 August 2017

1 reference

title

Current and future treatment modalities for Clostridium difficile-associated disease (English)

1 reference

4 August 2017

main subject

Clostridium difficile

0 references

author name string

Jennifer Halsey

series ordinal

1

1 reference

4 August 2017

language of work or name

1 reference

1 April 2008

1 reference

American Journal of Health-System Pharmacy

4 August 2017

published in

1 reference

4 August 2017

volume

65

1 reference

4 August 2017

issue

8

1 reference

4 August 2017

page(s)

705-715

1 reference

Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Comparison of toxinotyping and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

New types of toxin A-negative, toxin B-positive strains among Clostridium difficile isolates from Asia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Frequency of Binary Toxin Genes among Clostridium difficile Strains That Do Not Produce Large Clostridial Toxins

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

An epidemic, toxin gene-variant strain of Clostridium difficile

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Epidemic Clostridium difficile

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

The effects of storage conditions on viability of Clostridium difficile vegetative cells and spores and toxin activity in human faeces

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

The diagnosis of Clostridium difficile-associated diarrhea: comparison of Triage C. difficile panel, EIA for Tox A/B and cytotoxin assays

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Prospective multicenter evaluation of a new immunoassay and real-time PCR for rapid diagnosis of Clostridium difficile-associated diarrhea in hospitalized patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Guideline for Hand Hygiene in Health-Care Settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Reduction in nosocomial transmission of drug-resistant bacteria after introduction of an alcohol-based handrub

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Practice guidelines for the management of infectious diarrhea

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Systemic absorption of enteral vancomycin in a patient with pseudomembranous colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Clostridium difficile colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Severe Clostridium difficile colitis: the role of intracolonic vancomycin?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Evidence for biliary excretion of vancomycin into stool during intravenous therapy: potential implications for rectal colonization with vancomycin-resistant enterococci

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

In vitro and in vivo activities of nitazoxanide against Clostridium difficile

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Interruption of Recurrent Clostridium difficile-Associated Diarrhea Episodes by Serial Therapy with Vancomycin and Rifaximin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Intravenous immunoglobulin therapy for severe Clostridium difficile colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Inhibition of Clostridium difficile strains by intestinal Lactobacillus species.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

PCR amplification of the rDNA internal transcribed spacer region for differentiation of Saccharomyces cultures

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Are live saccharomyces yeasts harmful to patients?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Failure of dietary oligofructose to prevent antibiotic-associated diarrhoea

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Probiotics for recurrent Clostridium difficile disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Faecal short-chain fatty acids in patients with antibiotic-associated diarrhoea, before and after faecal enema treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Factors associated with failure of metronidazole in Clostridium difficile-associated disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Sudden increase of vancomycin-resistant enterococcal infections in a Korean tertiary care hospital: possible consequences of increased use of oral vancomycin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070077

31 March 2020

Identifiers

DOI

10.2146/AJHP070077

1 reference

4 August 2017

1 reference